Joey Jacobs, Chief and Chairman Executive Officer of Acadia, commented, Acadia’s second quarter revenue growth was primarily driven by the expansion in the number of beds in operation to 2 approximately,150 beds in 32 facilities at the end of the second quarter of 2012 from over 1,700 beds in 19 facilities at the end of the second quarter last year. Furthermore, we produced 7.3 percent development in same facility income for the second quarter of 2012, which was driven by a 9 primarily.2 percent increase in patient times for the period. The Company’s same service EBITDA margin increased 60 basis points to 23.0 percent for the quarter weighed against the same quarter in 2011.To 1 1:30 p.m., [Poster No. SA0378]Teriparatide treatment in Japanese topics with osteoporosis at risky of fracture: effect of bone mineral density and bone turnover markers during 12-month, randomized, placebo-controlled, double-blind and 12-month open-label study intervals Oct. 15, 5:45 p.m. 7:00 p.m., [Poster No. FR0376]Oct. 16, 11:30 a.m. To 1 1:30 p.m., [Poster No. SA0376]Association of fracture risk and quality of life as measured by the Osteoporosis Individual Assessment Questionnaire Oct. 16, 11:30 a.m. To 1 1:30 p.m., [Poster No. SA0358]Fracture incidence, quality of life and back pain in elderly women with osteoporosis treated with teriparatide: 36-month outcomes from the European Forsteo Observational Research Oct.